Nanobiotix Yönetim

Yönetim kriter kontrolleri 1/4

Nanobiotix CEO'su Laurent Levy, Mar2003 tarihinde atandı, in görev süresi 21.67 yıldır. in toplam yıllık tazminatı € 3.40M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.1% maaş ve 87.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.4% ine doğrudan sahiptir ve bu hisseler € 3.79M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.3 yıl ve 2 yıldır.

Anahtar bilgiler

Laurent Levy

İcra Kurulu Başkanı

€3.4m

Toplam tazminat

CEO maaş yüzdesi	12.1%
CEO görev süresi	21.7yrs
CEO sahipliği	2.4%
Yönetim ortalama görev süresi	5.3yrs
Yönetim Kurulu ortalama görev süresi	2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Laurent Levy'un ücretlendirmesi Nanobiotix'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€33m
Mar 31 2024	n/a	n/a	-€37m
Dec 31 2023	€3m	€411k	-€40m
Sep 30 2023	n/a	n/a	-€49m
Jun 30 2023	n/a	n/a	-€59m
Mar 31 2023	n/a	n/a	-€58m
Dec 31 2022	€1m	€380k	-€57m
Sep 30 2022	n/a	n/a	-€50m
Jun 30 2022	n/a	n/a	-€43m
Mar 31 2022	n/a	n/a	-€45m
Dec 31 2021	€4m	€380k	-€47m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€43m
Mar 31 2021	n/a	n/a	-€39m
Dec 31 2020	€818k	€330k	-€34m
Sep 30 2020	n/a	n/a	-€41m
Jun 30 2020	n/a	n/a	-€48m
Mar 31 2020	n/a	n/a	-€49m
Dec 31 2019	€2m	€330k	-€51m
Sep 30 2019	n/a	n/a	-€46m
Jun 30 2019	n/a	n/a	-€42m
Mar 31 2019	n/a	n/a	-€36m
Dec 31 2018	€1m	€300k	-€30m
Sep 30 2018	n/a	n/a	-€28m
Jun 30 2018	n/a	n/a	-€27m
Mar 31 2018	n/a	n/a	-€26m
Dec 31 2017	€861k	€253k	-€26m

Tazminat ve Piyasa: Laurent 'nin toplam tazminatı ($USD 3.56M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 786.80K ).

Tazminat ve Kazançlar: Laurent şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Laurent Levy (51 yo)

21.7yrs

Görev süresi

€3,396,084

Tazminat

Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Laurent Levy	Co-Founder	21.7yrs	€3.40m	2.4% € 3.8m
Bart Van Rhijn	Chief Financial & Business Officer and Member of Executive Board	3.4yrs	€1.50m	0% € 0
Anne-Juliette Hermant	Chief People Officer & Member of Executive Board	5.3yrs	€801.96k	0.30% € 466.2k
Louis Kayitalire	Chief Medical Officer	1.2yrs	€500.80k	Veri yok
Earl Bergey	Co-Founder	21.8yrs	Veri yok	Veri yok
Craig West	Senior Vice President of Investor Relations	no data	Veri yok	Veri yok
Brandon Owens	VP of Strategic Marketing & Corporate Communication	no data	Veri yok	Veri yok
Margaret Galluzzi	VP & Global Head of Clinical Operations	5.8yrs	Veri yok	Veri yok
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	2.8yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: 5NRA 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Leonard Farber	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board	no data	Veri yok	Veri yok
Enno Spillner	Independent Member of Supervisory Board	10.4yrs	€50.00k	Veri yok
Gary Phillips	Independent Chairman of Supervisory board	3.5yrs	€63.00k	Veri yok
Silvia Formenti	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Alain Herrera	Independent Member of Supervisory Board	11.4yrs	€35.00k	Veri yok
Anne-Marie Graffin	Independent Vice Chairman of the Supervisory Board	10.9yrs	€42.00k	Veri yok
Hisham Mehanna	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Stephane Champiat	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Jean Bourhis	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Thierry Baere	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Christophe Tourneau	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok
Nancy Lee	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 5NRA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Nanobiotix Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Recent updates

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş